RSV clinical trials at UCSF
1 research study open to eligible people
Showing trials for
Azithromycin Treatment for Respiratory Syncytial Virus-induced Respiratory Failure in Children
open to eligible people ages up to 2 years
The overarching hypothesis of the ARRC trial is that administration of Azithromycin (AZM) during acute, Respiratory Syncytial Virus (RSV)-induced respiratory failure will be beneficial, mediated through the matrix metalloproteinase (MMP)-9 pathway.
San Francisco, California and other locations
Our lead scientists for RSV research studies include Matt Zinter, MD.
Last updated: